Webinars and Tutorials

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 1: Practical Approaches to Delivering CAR T-Cell Therapy in 2L LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 1: Practical Approaches to Delivering CAR T-Cell Therapy in 2L LBCL

Overview

Speakers:
Dr. Ronan Foley
Dr. John Kuruvilla
20.11.2024
Duration: 18 mins 28 secs

During this discussion, Canadian CAR T experts review pivotal trial and current real-world evidence supporting use of CAR T cell for patients with large B-cell lymphoma (LBCL), with a focus on treatment in the second-line (2L) setting. Experts also discuss key clinical and practical considerations for all stages of the 2L CAR T journey, including synergies between referral and treatment centres.

Click here to evaluate this content

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 2: 2L CAR T for Primary Refractory LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 2: 2L CAR T for Primary Refractory LBCL

Overview

Speakers:
Dr. Ronan Foley
Dr. John Kuruvilla
20.11.2024
Duration: 13 mins 13 secs

In this video, Canadian CAR T experts review a clinical case of primary refractory LBCL. During this discussion, the experts review key clinical and logistical aspects for all stages of the 2L CAR T journey for patients with primary refractory LBCL, including patient eligibility and preparation.

Click here to evaluate this content

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 3: 2L CART for Primary Progressive LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 3: 2L CART for Primary Progressive LBCL

Overview

Speakers:
Dr. Ronan Foley
Dr. John Kuruvilla
20.11.2024
Duration: 16 mins 3 secs

In this video, Canadian CAR T experts review a clinical case of primary progressive LBCL. During this discussion, the experts review key clinical and logistical aspects for all stages of the 2L CAR T journey for patients with primary progressive LBCL, including the role of holding/bridging therapy and the importance of quick communication between referral and treatment centres.

Click here to evaluate this content

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 4: 2L CART for early relapsed (<12 months) LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 4: 2L CART for early relapsed (<12 months) LBCL

Overview

Speakers:
Dr. Ronan Foley
Dr. John Kuruvilla
20.11.2024
Duration: 17 mins 34 secs

In this video, Canadian CAR T experts review a clinical case of early relapsed (<12 months) LBCL. During this discussion, the experts review key clinical and logistical aspects for all stages of the 2L CAR T journey for patients with early relapsed (<12 months) LBCL, including the importance of re-biopsy and of referral and treatment centres partnership.

Click here to evaluate this content

Evolving Treatment Landscape for Mantle Cell Lymphoma (MCL) in Canada – Part 1

Evolving Treatment Landscape for Mantle Cell Lymphoma (MCL) in Canada – Part 1

Overview

Speakers:
Dr. Robert Puckrin
Eric Pesarachuk
22.06.2026
Duration: 28 mins 58 secs

This is a presentation titled “Evolving Treatment Landscape for Mantle Cell Lymphoma in Canada”. In part 1, Dr. Puckrin provides an overview of the TRIANGLE and ECHO protocols to integrate BTKi use into frontline therapy. He highlights considerations for high-risk patients, impacts on treatment sequencing, and considerations for patient preferences.

Click here to evaluate this content

Evolving Treatment Landscape for Mantle Cell Lymphoma (MCL) in Canada – Part 2

Expert Discussion on CAR T Therapy for Relapsed and Refractory Mantle Cell Lymphoma

Overview

Speakers:
Dr. Robert Puckrin
Eric Pesarachuk
22.06.2026
Duration: 17 mins 6 secs

This is a presentation titled “Evolving Treatment Landscape for Mantle Cell Lymphoma in Canada”. In part 2, Dr. Puckrin has a pragmatic discussion for approaches to choosing BTKi-containing regimens and CAR T-cell therapy in an era where BTKi use is moving up in treatment sequence.

Click here to evaluate this content

Evolving Treatment Landscape for Mantle Cell Lymphoma (MCL) in Canada – Part 3

Expert Discussion on CAR T Therapy for Relapsed and Refractory Mantle Cell Lymphoma

Overview

Speakers:
Dr. Robert Puckrin
Eric Pesarachuk
22.06.2026
Duration: 6 mins 11 secs

This is a presentation titled “Evolving Treatment Landscape for Mantle Cell Lymphoma in Canada”. In part 3, Dr. Puckrin highlights emerging T-cell engaging therapies and non-covalent BTKi treatments in R/R MCL.

Click here to evaluate this content